This study evaluates the efficacy, safety and tolerability of durvalumab, a PD-L1 monoclonal antibody, in combination with targeted anticancer agents in refractory NSCLC. Patients with LKB1 mutations were enrolled to receive durvalumab plus the PARP inhibitor olaparib. Here, CD274 is linked to non-small cell lung carcinoma.